Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients.
Peter L, Wendering DJ, Schlickeiser S, Hoffmann H, Noster R, Wagner DL, Zarrinrad G, Münch S, Picht S, Schulenberg S, Moradian H, Mashreghi MF, Klein O, Gossen M, Roch T, Babel N, Reinke P, Volk HD, Amini L, Schmueck-Henneresse M.
Peter L, et al. Among authors: moradian h.
Mol Ther Methods Clin Dev. 2022 Jun 9;25:52-73. doi: 10.1016/j.omtm.2022.02.012. Epub 2022 Feb 26.
Mol Ther Methods Clin Dev. 2022.
PMID: 35252469
Free PMC article.